New Issue: UBS prices $3.4 million 8.6% trigger callable yield notes on two stocks

By William Gullotti

Buffalo, N.Y., Feb. 12 – UBS AG, London Branch priced $3.4 million of 8.6% trigger callable yield notes due Jan. 29, 2026 linked to the stock performance of Bristol-Myers Squibb Co. and Pfizer Inc., according to a 424B2 filing with the Securities and Exchange Commission.

Interest is payable monthly.

The notes are callable at par on any monthly call date after six months.

The payout at maturity will be par unless any stock finishes below its 50% downside threshold level, in which case investors will receive a number of shares of the worst performer equal to $1,000 divided by that stock’s initial level.

UBS Financial Services Inc. is the agent.

Issuer:	UBS AG, London Branch
Issue:	Trigger callable yield notes
Underlying stocks:	Bristol-Myers Squibb Co., Pfizer Inc.
Amount:	$3.4 million
Maturity:	Jan. 29, 2026
Coupon:	8.6% per year, payable monthly
Price:	Par
Payout at maturity:	Par unless any stock finishes below downside threshold, in which case receive a number of shares of the worst performer per note equal to its equity ratio
Call option:	At par on any monthly evaluation date after six months
Initial levels:	$50.24 for Bristol-Myers Squibb, $28.33 for Pfizer
Downside thresholds:	$25.12 for Bristol-Myers Squibb, $14.17 for Pfizer; 50% of initial levels
Equity ratios:	19.9045 for Bristol-Myers Squibb, 35.2983 for Pfizer; shares delivered per note
Pricing date:	Jan. 24
Settlement date:	Jan. 29
Agent:	UBS Financial Services Inc.
Fees:	1.25%
Cusip:	90279WQ31

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.